124 related articles for article (PubMed ID: 15541258)
1. Effect of amiodarone on the plasma levels of metoprolol.
Werner D; Wuttke H; Fromm MF; Schaefer S; Eschenhagen T; Brune K; Daniel WG; Werner U
Am J Cardiol; 2004 Nov; 94(10):1319-21. PubMed ID: 15541258
[TBL] [Abstract][Full Text] [Related]
2. Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia.
Fukumoto K; Kobayashi T; Tachibana K; Kato R; Tanaka K; Komamura K; Kamakura S; Kitakaze M; Ueno K
Drug Metab Pharmacokinet; 2006 Dec; 21(6):501-5. PubMed ID: 17220566
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
[TBL] [Abstract][Full Text] [Related]
4. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.
Ismail R; Teh LK
J Clin Pharm Ther; 2006 Feb; 31(1):99-109. PubMed ID: 16476126
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
[TBL] [Abstract][Full Text] [Related]
6. Effects of antiarrhythmic drug therapy on atrioventricular nodal function during atrial fibrillation in humans.
Mangin L; Vinet A; Pagé P; Glass L
Europace; 2005 Sep; 7 Suppl 2():71-82. PubMed ID: 16102505
[TBL] [Abstract][Full Text] [Related]
7. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
9. Plasma digoxin concentration fluctuations associated with timing of plasma sampling and amiodarone administration.
DeVore KJ; Hobbs RA
Pharmacotherapy; 2007 Mar; 27(3):472-5. PubMed ID: 17316159
[TBL] [Abstract][Full Text] [Related]
10. Toward optimal treatment in women: the effect of sex on metoprolol-diphenhydramine interaction.
Sharma A; Pibarot P; Pilote S; Dumesnil JG; Arsenault M; Bélanger PM; Meibohm B; Hamelin BA
J Clin Pharmacol; 2010 Feb; 50(2):214-25. PubMed ID: 19948945
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure.
Sharp CF; Gardiner SJ; Jensen BP; Roberts RL; Troughton RW; Lainchbury JG; Begg EJ
Pharmacogenomics J; 2009 Jun; 9(3):175-84. PubMed ID: 19365402
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine.
Mikami A; Ohtani H; Hori S; Sawada Y
Int J Clin Pharmacol Ther; 2013 May; 51(5):374-82. PubMed ID: 23357843
[TBL] [Abstract][Full Text] [Related]
13. [Rationale and methods of the UNAMET study (dose- and CYP2D6-genotype-dependent adverse drug reactions of metoprolol)--a contribution to quality improvement in pharmacotherapy].
Fux R; Meisner C; Schwab M; Lorenz G; Mörike K; Gleiter CH
Z Arztl Fortbild Qualitatssich; 2004 Nov; 98(8):689-94. PubMed ID: 15646732
[TBL] [Abstract][Full Text] [Related]
14. Amiodarone therapy for atrial rhythm control: insights gained from a single center experience.
Chandhok S; Schwartzman D
J Cardiovasc Electrophysiol; 2007 Jul; 18(7):714-8. PubMed ID: 17504255
[TBL] [Abstract][Full Text] [Related]
15. Dronedarone: in quest of the ideal antiarrhythmic drug.
Kayser SR
Prog Cardiovasc Nurs; 2007; 22(4):221-4. PubMed ID: 18059201
[No Abstract] [Full Text] [Related]
16. QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.
Kounas SP; Letsas KP; Sideris A; Efraimidis M; Kardaras F
Pacing Clin Electrophysiol; 2005 May; 28(5):472-3. PubMed ID: 15869686
[TBL] [Abstract][Full Text] [Related]
17. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation.
Yin Y; Dalal D; Liu Z; Wu J; Liu D; Lan X; Dai Y; Su L; Ling Z; She Q; Luo K; Woo K; Dong J
Eur Heart J; 2006 Aug; 27(15):1841-6. PubMed ID: 16825288
[TBL] [Abstract][Full Text] [Related]
18. The use of intravenous amiodarone for chemical conversion of atrial fibrillation.
Dale K; White CM
Conn Med; 2006 Aug; 70(7):433-7. PubMed ID: 16937720
[No Abstract] [Full Text] [Related]
19. [Amiodarone--still a useful antiarrhythmic drug].
Gjesdal K
Tidsskr Nor Laegeforen; 2008 Jun; 128(13):1532-3. PubMed ID: 18587462
[TBL] [Abstract][Full Text] [Related]
20. Effect of low-dose amiodarone and magnesium combination on atrial fibrillation after coronary artery surgery.
Cagli K; Ozeke O; Ergun K; Budak B; Demirtas E; Birincioglu CL; Pac M
J Card Surg; 2006; 21(5):458-64. PubMed ID: 16948756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
